AQST vs BAX: fair value comparison
Aquestive Therapeutics, Inc. and Baxter International Inc. · Updated 2026-10-19
AQST has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AQST currently ranks higher by quality score.
| AQST | BAX | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $3.78 | $24.35 |
| 12-month range | $2.95–$7.01 | $15.80–$28.35 |
| Rank by discount to fair value | — | #40 of 108 Healthcare |
| Rank by quality score | #150 of 301 Healthcare | #151 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | High |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: AQST fair value analysis · BAX fair value analysis